Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM35VEI)

Drug Name
3-(Benzyloxy)Pyridin-2-Amine Drug Info
Synonyms
2-Amino-3-benzyloxypyridine; 24016-03-3; 3-(BENZYLOXY)PYRIDIN-2-AMINE; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
90334
CAS Number
CAS 24016-03-3
TTD Drug ID
DM35VEI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukotriene A-4 hydrolase (LTA4H)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bestatin DM8L9D4 Acute myeloid leukaemia 2A60 Approved [2]
LYS006 DMI17QR Ulcerative colitis DD71 Phase 2 [3]
Acebilustat DM19UTO Chronic blistering skin disorder ME63.3 Phase 1 [4]
DG051 DM3I0GS Myocardial infarction BA41-BA43 Discontinued in Phase 2 [5]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [1]
JNJ-10392980 DMZH0K8 Discovery agent N.A. Investigative [6]
4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ Discovery agent N.A. Investigative [7]
2-(4-phenoxyphenoxy)ethanamine DM7TBUJ Discovery agent N.A. Investigative [8]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO Discovery agent N.A. Investigative [9]
2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole DMMYJ3R Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [10]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [10]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [11]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [12]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [10]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [13]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [13]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [13]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [13]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene A-4 hydrolase (LTA4H) TTXZEAJ LKHA4_HUMAN Inhibitor [1]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
3 Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A(4) Hydrolase. J Med Chem. 2021 Feb 25;64(4):1889-1903.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
6 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
7 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
8 Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
9 Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
10 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
11 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
12 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
13 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.